JAMA Oncology

@JAMAOnc

JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.

Chicago, IL

ja.ma/tjamaoncology

Beigetreten im September 2014

18Tsd.Posts 49Tsd.Follower 510Folge ich

Was dir gefallen könnte

@JCO_ASCO

@TheLancetOncol

@Annals_Oncology

@theNCI

@ASCOPost

@FDAOncology

@ASCO

@OncJournal

@myESMO

@OncoAlert

@MDAndersonNews

@AACR

@ESMO_Open

@OncLive

@NatRevClinOncol

JAMA Oncology

16.11.

💬 Viewpoint: #Medicaid cuts and work requirements in the 2025 budget law risk reduced access to cancer prevention, delayed diagnoses, later-stage disease at presentation, and caused worse cancer outcomes. ja.ma/3JJX22H

JAMAOnc's tweet image. 💬 Viewpoint: #Medicaid cuts and work requirements in the 2025 budget law risk reduced access to cancer prevention, delayed diagnoses, later-stage disease at presentation, and caused worse cancer outcomes. ja.ma/3JJX22H

JAMA Oncology

16.11.

💬 Viewpoint: Trust in medicine has declined due to the #COVID19 pandemic and abundant online health information, highlighting the need for transparent, patient-focused communication. ja.ma/4hWen4W

JAMAOnc's tweet image. 💬 Viewpoint: Trust in medicine has declined due to the #COVID19 pandemic and abundant online health information, highlighting the need for transparent, patient-focused communication. ja.ma/4hWen4W

JAMA Oncology

15.11.

Among patients with advanced urothelial cancer, upfront enfortumab vedotin dose reduction was linked to a 50% reduction in treatment interruption risk but did not compromise overall survival. ja.ma/47L9DdG

JAMAOnc's tweet image. Among patients with advanced urothelial cancer, upfront enfortumab vedotin dose reduction was linked to a 50% reduction in treatment interruption risk but did not compromise overall survival. ja.ma/47L9DdG

JAMA Oncology

15.11.

💬 Viewpoint: #OvarianCancer's unique attributes complicate early detection, necessitating personalized risk-based strategies for better prevention and outcomes. ja.ma/3Jwfzzu

JAMAOnc's tweet image. 💬 Viewpoint: #OvarianCancer's unique attributes complicate early detection, necessitating personalized risk-based strategies for better prevention and outcomes. ja.ma/3Jwfzzu

JAMA Oncology

14.11.

Cross-disciplinary international position statement summarizes the current understanding of CV toxic effects associated with ICI therapy, including strategies for diagnosis, treatment, and potential rechallenge and an outline of relevant knowledge gaps. ja.ma/47FVdNs

JAMAOnc's tweet image. Cross-disciplinary international position statement summarizes the current understanding of CV toxic effects associated with ICI therapy, including strategies for diagnosis, treatment, and potential rechallenge and an outline of relevant knowledge gaps. ja.ma/47FVdNs

JAMA Oncology

13.11.

Among women under 50, those with the highest ultraprocessed food intake had 45% higher odds of early-onset colorectal conventional adenomas versus those with the lowest intake; no significant association was seen for serrated lesions. ja.ma/4r2lqxo

JAMAOnc's tweet image. Among women under 50, those with the highest ultraprocessed food intake had 45% higher odds of early-onset colorectal conventional adenomas versus those with the lowest intake; no significant association was seen for serrated lesions. ja.ma/4r2lqxo

JAMA Oncology

13.11.

In a nonrandomized phase 2 trial of adults with advanced dMMR/MSI-H noncolorectal cancers, combined nivolumab/ipilimumab showed an objective response rate of 63% and 6-month progression-free survival rate of 71%. ja.ma/4i68zWQ

JAMAOnc's tweet image. In a nonrandomized phase 2 trial of adults with advanced dMMR/MSI-H noncolorectal cancers, combined nivolumab/ipilimumab showed an objective response rate of 63% and 6-month progression-free survival rate of 71%. ja.ma/4i68zWQ

JAMA Oncology

12.11.

💬 Viewpoint: Addressing food insecurity, particularly among #cancer patients, requires systemic policy changes that prioritize sustainable funding and support for large-scale food assistance programs. ja.ma/4qRuiWy

JAMAOnc's tweet image. 💬 Viewpoint: Addressing food insecurity, particularly among #cancer patients, requires systemic policy changes that prioritize sustainable funding and support for large-scale food assistance programs. ja.ma/4qRuiWy

JAMA Oncology

11.11.

💬 Viewpoint: Oncology is shifting toward personalized, less aggressive treatments for "good-risk" metastatic prostate cancer and similar tumors, prioritizing efficacy and quality of life over overtreatment. ja.ma/43g6Yrb

JAMAOnc's tweet image. 💬 Viewpoint: Oncology is shifting toward personalized, less aggressive treatments for "good-risk" metastatic prostate cancer and similar tumors, prioritizing efficacy and quality of life over overtreatment. ja.ma/43g6Yrb

JAMA Oncology

10.11.

A 78-year-old man with a history of nonmelanoma skin cancers presented with left-sided upper and lower facial weakness. What is your diagnosis? ja.ma/49DWPs8

JAMAOnc's tweet image. A 78-year-old man with a history of nonmelanoma skin cancers presented with left-sided upper and lower facial weakness. What is your diagnosis? ja.ma/49DWPs8

JAMA Oncology

10.11.

The JAMA Network invites research submissions on #AI in clinical settings, prioritizing rigorous methodologies and validation for informed medical practice. 🔗 See the full submission criteria: ja.ma/4hhwv92

JAMAOnc's tweet image. The JAMA Network invites research submissions on #AI in clinical settings, prioritizing rigorous methodologies and validation for informed medical practice.

🔗 See the full submission criteria: ja.ma/4hhwv92

JAMA Oncology

09.11.

Viewpoint: GLP-1 receptor agonists induce weight loss but may lead to pronounced muscle mass reduction, raising concerns for patients with cancer at risk of frailty and decreased physical function. ja.ma/49LbiT8

JAMAOnc's tweet image. Viewpoint: GLP-1 receptor agonists induce weight loss but may lead to pronounced muscle mass reduction, raising concerns for patients with cancer at risk of frailty and decreased physical function. ja.ma/49LbiT8

JAMA Oncology

09.11.

Rare pathogenic variants in 16 #cancer predisposition genes were linked to both single and multiple cancer diagnoses, suggesting multigene panel testing could be beneficial. ja.ma/4hMGweD

JAMAOnc's tweet image. Rare pathogenic variants in 16 #cancer predisposition genes were linked to both single and multiple cancer diagnoses, suggesting multigene panel testing could be beneficial. ja.ma/4hMGweD

JAMA Oncology

08.11.

Semaglutide and tirzepatide prescriptions for obesity have increased among patients with preexisting cancer, with notable variation by cancer type and absence of cancer-specific guidelines. ja.ma/3JzvqNE

JAMAOnc's tweet image. Semaglutide and tirzepatide prescriptions for obesity have increased among patients with preexisting cancer, with notable variation by cancer type and absence of cancer-specific guidelines. ja.ma/3JzvqNE

JAMA Oncology

07.11.

AI technologies hold potential to enhance acute myeloid leukemia management by improving risk stratification, early detection, and treatment optimization through integration of clinical, morphological, and genetic data. ja.ma/3Xk9au8

JAMAOnc's tweet image. AI technologies hold potential to enhance acute myeloid leukemia management by improving risk stratification, early detection, and treatment optimization through integration of clinical, morphological, and genetic data. ja.ma/3Xk9au8

JAMA Oncology

06.11.

Older age in unrelated donors linked to lower survival in allogeneic hematopoietic cell transplant with conventional calcineurin inhibitor-based graft-vs-host disease prophylaxis, but this association is mitigated with posttransplant cyclophosphamide. ja.ma/4ornu09

JAMAOnc's tweet image. Older age in unrelated donors linked to lower survival in allogeneic hematopoietic cell transplant with conventional calcineurin inhibitor-based graft-vs-host disease prophylaxis, but this association is mitigated with posttransplant cyclophosphamide.

ja.ma/4ornu09

JAMA Oncology

05.11.

Consistent moderate physical activity—about 17 metabolic equivalent task-hours/week over 3 decades—was associated with optimally reduced risk of digestive system cancers in a large cohort study. ja.ma/49pLUlS

JAMAOnc's tweet image. Consistent moderate physical activity—about 17 metabolic equivalent task-hours/week over 3 decades—was associated with optimally reduced risk of digestive system cancers in a large cohort study. ja.ma/49pLUlS

JAMA Oncology

05.11.

While the use of fertility-preserving #HormonalTherapy for early-stage endometrial #cancer has increased, survival outcomes are comparable to #hysterectomy in patients under 40. ja.ma/3LdSq5i

JAMAOnc's tweet image. While the use of fertility-preserving #HormonalTherapy for early-stage endometrial #cancer has increased, survival outcomes are comparable to #hysterectomy in patients under 40. ja.ma/3LdSq5i

JAMA Oncology

04.11.

💬 Editorial: Patients with limited nodal disease after neoadjuvant therapy may avoid axillary lymph node dissection by using limited axillary surgery and radiation. ja.ma/47vSTad

JAMAOnc's tweet image. 💬 Editorial: Patients with limited nodal disease after neoadjuvant therapy may avoid axillary lymph node dissection by using limited axillary surgery and radiation. ja.ma/47vSTad

JAMA Oncology

04.11.

Using the MARI protocol, response-guided axillary treatment in patients with limited nodal disease after primary systemic treatment showed a low risk of axillary recurrence. ja.ma/48VP14W

JAMAOnc's tweet image. Using the MARI protocol, response-guided axillary treatment in patients with limited nodal disease after primary systemic treatment showed a low risk of axillary recurrence. ja.ma/48VP14W

Toni Choueiri, MD

@DrChoueiri

Vivek Subbiah, MD

@VivekSubbiah

Paolo Tarantino

@PTarantinoMD

ESMO - Eur. Oncology

@myESMO

Matteo Lambertini, MD PhD

@matteolambe

Erika Hamilton, MD, FASCO

@ErikaHamilton9

OncLive.com

@OncLive

Annals of Oncology

@Annals_Oncology

SABCS

@SABCSSanAntonio

ASCO

@ASCO

NatureRevClinOncol

@NatRevClinOncol

Hope Rugo

@hoperugo

Stephanie Graff, MD, FACP, FASCO

@DrSGraff

Drew Moghanaki

@DrewMoghanaki

Sumanta K. Pal, MD, FASCO

@montypal

FabriceAndre

@FAndreMD

Sara Tolaney

@stolaney1

Pashtoon Kasi MD, MS

@pashtoonkasi

Daniel E Spratt

@DrSpratticus

Journal of Clinical Oncology

@JCO_ASCO

Cory Eaton

@cdjeatonlf1

ankur jain

@drsurg_ankur

Oncora Health

@OncoraHealth

Nick

@rumps11

Greg Gago

@GagoGreg26560

aspire

@aspire14893656

Yumiko I

@y0430g_

peiting chen

@peitingchen912

David Gomez

@DavidGomezMed

Peter Botos

@PBb9816

ltandj ltandj

@ltandj

Matthew Stack

@MatthewStack20

talking drums (dondo)

@azinga

DR. KYARUZI

@kyaruzi_dr

Okonkwo Ejike Kenneth

@OkonkwoEjikeKe1

🦋scott🦋

@ScottieJoh63009

Amadu Sufyanu

@AmaduSufyanu2

Ngetich Edmonds

@EdmondsEddy

panweitt

@panweitt

Phuc Sinh Le

@lephucsinh82

Rogelio Benfield MD

@GrbRoger

stenotrophomonas maltophilia

@ibrahimmarro

Canguo Piao

@YongqingPark

mozhdeh

@mozhdeh23127230

Masahiro Kuno, MD

@MasahiroKuno

Marc Uemura

@MarcUemura

RskMgmt

@RskMgmt_

Deus Muhirwa

@deus_muhirwa

Jarimonio

@jarimasl

Harshit Garg MCh MBBS MD

@Garg_H

Mauro Carretta Di Stasi

@MauroCar6

Jake Block

@Jake_Block_

MJosé Juan

@mjuanfi81

FELIPE AGUDELO

@AGUDELOA12

Helen Watson

@HWatson2024

idil7

@idyll07

Sari Gezzar-Dandashi

@SariGD1989

koichi

@koichi022541

こな医

@resp_fit9029

Yuliangel Fernández A.

@yuliangelfa26

大学受験とツブフツクリ

@tsubu_futsu

Jun Shimekawa

@jun_shimekawa

Balan Ionela

@BalanIonelaT

AtsushiTakahashiHBP

@AtsushiHbp

debbie beausang

@BeausangDebbie

Aida

@Aida57063907

Ivo W Tremont

@tremont_w

まゆ

@mayumochi1027

すずら

@peaaach_orange

Chinedu

@ChineduOkeagu

Toni Choueiri, MD

@DrChoueiri

Vivek Subbiah, MD

@VivekSubbiah

ESMO - Eur. Oncology

@myESMO

Matteo Lambertini, MD PhD

@matteolambe

Erika Hamilton, MD, FASCO

@ErikaHamilton9

OncLive.com

@OncLive

ASCO

@ASCO

Stephanie Graff, MD, FACP, FASCO

@DrSGraff

Sumanta K. Pal, MD, FASCO

@montypal

Pashtoon Kasi MD, MS

@pashtoonkasi

Daniel E Spratt

@DrSpratticus

Journal of Clinical Oncology

@JCO_ASCO

The ASCO Post

@ASCOPost

Harold J. Burstein, MD, PhD, FASCO

@DrHBurstein

ASTRO

@ASTRO_org

Neeraj Agarwal, MD, FASCO

@neerajaiims

d.planchard

@dplanchard

soria

@jsoriamd

The Lancet Oncology

@TheLancetOncol

H. Jack West, MD, FASCO

@JackWestMD

Kirsten Bibbins-Domingo

@KBibbinsDomingo

Eric J. Small, MD, FASCO

@ASCOPres

Optimal Cancer Care Alliance

@OCCA_Cancer

APOS

@APOSHQ

Gary Lyman 🇺🇸🇪🇺🇺🇦💛💙

@gary_lyman

Maciej M Mrugala, MD, PhD, MPH, FAAN

@MrugalaMaciej

Pamela Kunz, MD, FASCO

@PamelaKunzMD

Anne Marie Mercurio

@chemobrainfog

Laurie Glimcher MD

@LGlimcherMD

Canadian Gastric Cancer Association

@CanadianGastric

Syed A. Ahmad

@SyedAAhmad5

Jane Maher💙also on Bluesky

@Maherjane

Richard Simcock

@BreastDocUK

JAMA Career Center

@JAMACareerCtr

St. Jude Research

@StJudeResearch

AMA Manual of Style

@AMAManual

Dana-Farber Data Science

@dfcidatascience

GO2 for Lung Cancer

@GO2forLungCancr

Daniel Goldstein MD

@drdgoldstein

Architectural Medicine

@ArchMedicine

George W Sledge MD

@GeorgeSledge51

Yelena Y. Janjigian MD

@YJanjigianMD

Philip Lupo

@plupo1

Sam Klempner

@KlempnerSam

Thomas Uldrick, MD

@ThomasUldrick

National Foundation for Cancer Research

@NFCR

Reshma Jagsi

@reshmajagsi

Charles Ferté

@charles_ferte

Benjamin Besse

@BenjaminBesseMD

Plenary Session Podcast 🎙️

@Plenary_Session

Mina S. Sedrak

@minasedrakmd

Cancer and Aging Research Group (CARG) #GeriOnc

@myCARG

Alfredo Addeo MD

@Alfdoc2

William Dale, MD, PhD, FASCO

@WilliamDale_MD

Thomas LeBlanc, MD, MA, MHS, FAAHPM, FASCO

@tomleblancMD

Shannon Westin, MD, MPH, FASCO

@ShannonWestin

Deanna Teoh, M.D., M.S., FACOG

@DeannaTeoh

Martina Murphy, MD

@DrMMurphy

Sandip Patel MD FASCO

@PatelOncology

Lecia Sequist, MD, MPH, FASCO

@LeciaSequist

RahmaWarsame MD

@RahmaWarsameMD

Talal Hilal 🩺

@THilalMD

David Steensma, MD

@DavidSteensma

Arturo LoAIza-Bonilla, MD MSEd

@DrArturoAI

Julie Hallet

@HalletJulie

Nausheen Akhter, MD

@nakhtermd

Pearson Lab

@lab_pearson

Lauren E. Colbert, MD MSCR

@colbertle

United States Trends

1. Good Thursday 25.4K posts
2. Happy Friday Eve N/A
3. #thursdaymotivation 1,494 posts
4. #ThursdayThoughts 1,461 posts
5. #thursdayvibes 2,104 posts
6. #หลิงออมปฏิทินช่อง3ปี2569 655K posts
7. LINGORM CH3 CALENDAR SIGN 652K posts
8. Nnamdi Kanu 57.4K posts
9. #ProofOfFortification N/A
10. FEMA 77.5K posts
11. But Jesus 22.2K posts
12. Knicks 14.1K posts
13. Shamet 3,141 posts
14. Crockett 58.3K posts
15. GM CT 23.9K posts
16. The 2024 91.1K posts
17. NO CAP 15K posts
18. FREE HAT 1,828 posts
19. Sam Harris 3,766 posts
20. Hire American 5,282 posts

Was dir gefallen könnte

Something went wrong.

Something went wrong.